Sionna Therapeutics plans to cut its workforce by approximately 46% and expects about $6.4 million in restructuring and related charges. The move is intended to concentrate resources on SION-451 and SION-2222, extend cash runway into the second half of 2029 and support a Phase 2a trial expected to begin in the first quarter of 2027.

Key Highlights

  • Employee severance and related post-employment benefits account for approximately $5.3 million of the restructuring estimate.
  • Sionna will wind down vendor arrangements linked to the SION-719 add-on program.
  • Stock Options with exercise prices above $18.00 will be repriced for eligible employees who remain after the workforce reduction.

Sionna Therapeutics, Inc. (NASDAQ: SION) plans to reduce its workforce by approximately 46% and expects about $6.4 million in restructuring and related charges.

Sionna Sets Restructuring Charges and Leadership Changes

Caroline Stark Beer’s employment as chief Business officer ends without cause on September 15, 2026, subject to the terms of her severance plan. Charlotte McKee, Elena Ridloff and Jennifer Fitzpatrick will assume added research and development, business, and program management responsibilities, respectively, with no compensation changes.

Option Repricing

Options under the 2025 Plan with exercise prices above $18.00, along with certain options priced at $18.00, will be reset to the common stock’s closing price on September 17, 2026, for eligible employees who remain after the reduction. The repriced awards will revert to their original exercise prices if exercised before the retention period ends; that period ends upon the earliest of specified events. Sionna expects the dual combination Phase 2a proof-of-concept trial to begin in the first quarter of 2027.